US Pharma Company Artelo Announces Launch of Solana Reserve Asset Strategy
BlockBeats News, August 4th, Pharmaceutical company Artelo Biosciences (Nasdaq: ARTL) announced the completion of a $9.475 million off-market private placement, which will be used to launch a Solana (SOL)-centered digital asset reserve strategy, making it the first publicly traded pharmaceutical company to include SOL as a reserve asset.
This private placement includes the issuance of common stock (or pre-funded warrants) at a price of $10.45 per share, as well as two tranches of warrants with exercise prices of $10.20 and $50, respectively, with a three-year term. The transaction is expected to be completed on August 5, 2025.
You may also like
How to choose between buying discounted ETH, Bitmine, and SharpLink?
Semiconductor stocks plummet, yet Anthropic wants to create a 2nm chip
A South Korean company that learned the strategy of hoarding coins, from a bull market to delisting?
Where is Zhao Changpeng's billion-dollar investment going? YZi Labs' investment landscape fully revealed
Ethereum Foundation Report: A Basic Guide to Ethereum for Governments and Financial Institutions
A pre-announced harvesting case: After the cryptocurrency price dropped by 99%, the public chain Saga exited to transform into AI
When American giants collectively "defect" from Chinese AI models
BIS Report Compliance Observation: The Real Risks of Stablecoins, Not Just "Depegging"
Portugal 2-1 Croatia: Ronaldo's 20-Year Knockout-Stage Drought Ends With a Debt Finally Collected
Portugal beat Croatia 2-1 in the 2026 global football championship's knockout rounds as Ronaldo scored his first-ever knockout-stage goal, Gonçalo Ramos struck a stoppage-time winner, and VAR ruled out a late equalizer for offside.
